<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "journalpublishing.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="2.0" xml:lang="en" article-type="letter"><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Dermatol</journal-id><journal-id journal-id-type="publisher-id">derma</journal-id><journal-id journal-id-type="index">29</journal-id><journal-title>JMIR Dermatology</journal-title><abbrev-journal-title>JMIR Dermatol</abbrev-journal-title><issn pub-type="epub">2562-0959</issn><publisher><publisher-name>JMIR Publications</publisher-name><publisher-loc>Toronto, Canada</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">v8i1e65579</article-id><article-id pub-id-type="doi">10.2196/65579</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group></article-categories><title-group><article-title>Rising Leishmaniasis Cases in the United States Based on Registry Data From 2007 to 2023 and the Vital Role of Health Care Providers in Awareness and Management</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Panlilio</surname><given-names>Mia</given-names></name><degrees>BA</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Martini</surname><given-names>Olnita</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Tchernogorova</surname><given-names>Elizabeth</given-names></name><degrees>BA</degrees><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Carboni</surname><given-names>Alexa</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Duffle</surname><given-names>Danielle</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Torgerson</surname><given-names>Leslie</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">*</xref></contrib></contrib-group><aff id="aff1"><institution>Department of Biomedical Sciences, College of Osteopathic Medicine, Rocky Vista University</institution><addr-line>8401 S Chambers Rd</addr-line><addr-line>Englewood</addr-line><addr-line>CO</addr-line><country>United States</country></aff><aff id="aff2"><institution>College of Osteopathic Medicine, Rocky Vista University</institution><addr-line>Ivins</addr-line><addr-line>UT</addr-line><country>United States</country></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Dellavalle</surname><given-names>Robert</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name name-style="western"><surname>Mondal</surname><given-names>Dinesh</given-names></name></contrib><contrib contrib-type="reviewer"><name name-style="western"><surname>Kathuria</surname><given-names>Sushruta</given-names></name></contrib></contrib-group><author-notes><corresp>Correspondence to Mia Panlilio, BA, Department of Biomedical Sciences, College of Osteopathic Medicine, Rocky Vista University, 8401 S Chambers Rd, Englewood, CO, 80112, United States, 1 303-373-2008; <email>mia.panlilio@ut.rvu.edu</email></corresp><fn fn-type="equal" id="equal-contrib1"><label>*</label><p>all authors contributed equally</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>6</month><year>2025</year></pub-date><volume>8</volume><elocation-id>e65579</elocation-id><history><date date-type="received"><day>19</day><month>08</month><year>2024</year></date><date date-type="rev-recd"><day>05</day><month>03</month><year>2025</year></date><date date-type="accepted"><day>06</day><month>03</month><year>2025</year></date></history><copyright-statement>&#x00A9; Mia Panlilio, Olnita Martini, Elizabeth Tchernogorova, Alexa Carboni, Danielle Duffle, Leslie Torgerson. Originally published in JMIR Dermatology (<ext-link ext-link-type="uri" xlink:href="http://derma.jmir.org">http://derma.jmir.org</ext-link>), 20.6.2025. </copyright-statement><copyright-year>2025</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Dermatology, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link ext-link-type="uri" xlink:href="http://derma.jmir.org">http://derma.jmir.org</ext-link>, as well as this copyright and license information must be included.</p></license><self-uri xlink:type="simple" xlink:href="https://derma.jmir.org/2025/1/e65579"/><abstract><p>This letter highlights the increasing incidence of leishmaniasis cases in the United States, using the available data from Texas, and underscores the need for heightened awareness among health care providers regarding leishmaniasis diagnosis and prevention.</p></abstract><kwd-group><kwd>leishmaniasis</kwd><kwd>leishmania</kwd><kwd>sandfly</kwd><kwd>awareness</kwd><kwd>management</kwd><kwd>health care provider</kwd><kwd>dermatology</kwd><kwd>dermatologist</kwd><kwd>skin condition</kwd><kwd>skin</kwd><kwd>dermis</kwd><kwd>United States</kwd><kwd>low-income population</kwd><kwd>low-income area</kwd></kwd-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Leishmaniasis is a parasitic infection caused by the protozoa <italic>Leishmania</italic> via the female sandfly vector, including <italic>Phlebotomus</italic> and <italic>Lutzmyia</italic>, which are most prevalent in the tropics and subtropics [<xref ref-type="bibr" rid="ref1">1</xref>]. Leishmaniasis infection can manifest in different forms, including localized cutaneous leishmaniasis, mucocutaneous leishmaniasis, and visceral leishmaniasis (known as <italic>kala-azar</italic>) [<xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref>]. Over 80 cases of endemic cutaneous leishmaniasis have been reported as endemic in the United States since 2017, specifically arising in Texas, Oklahoma, and Arizona [<xref ref-type="bibr" rid="ref2">2</xref>]. Currently, leishmaniasis is only a reportable disease in Texas, meaning many cases across the United States may go unreported. Additionally, McIlwee et al [<xref ref-type="bibr" rid="ref2">2</xref>] found that only 20% of cases were reported to the Texas Department of State Health Services (DSHS) between 2007 to 2023, despite such reporting being a legal requirement, potentially highlighting medical providers&#x2019; lack of awareness regarding human leishmaniasis. As environmental temperatures increase globally, the leishmaniasis vector and reservoir habitats have been expanding northward, potentially reaching southeastern Canada by 2050 [<xref ref-type="bibr" rid="ref3">3</xref>]. By 2080, over 27 million North Americans could be at risk [<xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref4">4</xref>]. By using the available data from Texas, our aim is to acknowledge and highlight the potential risk of leishmaniasis cases in the United States, educate providers on the signs and symptoms, and encourage patient education on how to mitigate leishmaniasis spread.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><p>Leishmaniasis case data were collected from 2007 to 2023 through the Texas DSHS, which tracks leishmaniasis cases reported by providers in Texas [<xref ref-type="bibr" rid="ref5">5</xref>]. Texas population data for 2007 to 2023 were sourced from the US Census Bureau, which collects data through surveys, censuses, and governmental administrative data. Incidence rates for leishmaniasis in Texas were then calculated for 2007 to 2023.</p></sec><sec id="s3" sec-type="results"><title>Results</title><p>Between 2007 and 2023, the number of reported leishmaniasis cases in Texas fluctuated but trended upward over time, along with rising temperatures (<xref ref-type="fig" rid="figure1">Figures 1</xref> and <xref ref-type="fig" rid="figure2">2</xref>). The number of cases rose from 9 in 2007 to a peak of 15 in 2018, with a slight decline afterward, reaching 9 again in 2023. Leishmaniasis incidence also increased from 0.378 per million in 2007 to 0.524 per million in 2018. A substantial drop to 0.304 per million occurred in 2020, with the 2023 incidence being slightly lower at 0.299 per million, indicating the disease&#x2019;s ongoing presence.</p><fig position="float" id="figure1"><label>Figure 1.</label><caption><p>Leishmaniasis cases and incidence in Texas from 2007 to 2023. Annual reported leishmaniasis cases and incidence per million people in Texas are shown by the blue bars and orange line, respectively.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="derma_v8i1e65579_fig01.png"/></fig><fig position="float" id="figure2"><label>Figure 2.</label><caption><p>Annual reported leishmaniasis cases compared to the average temperature ([&#x00B0;F&#x2005;&#x2212;&#x2005;32][0.556]&#x2005;=&#x2005;&#x00B0;C) per year from 2007 to 2023.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="derma_v8i1e65579_fig02.png"/></fig></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><sec id="s4-1"><title>Principal Findings</title><p>The Texas data from 2007 to 2023 highlight a continual increasing trend in leishmaniasis incidence, which aligns with broader concerns regarding the emergence of this parasitic infection in the United States. The increase in reported cases&#x2014;particularly seen from 2013 to 2018&#x2014;may suggest improved awareness and reporting among health care providers. The fluctuations in recent years could be explained by the underreporting of cases (ie, only an estimated 20% of cases were reported to the Texas DSHS), which poses a significant epidemiologic issue.</p><p>The observed peaks in incidence, particularly in 2018, underscore the need for continued vigilance among health care providers in recognizing and diagnosing leishmaniasis. The drastic drop in incidence observed in 2020 is likely attributable to the COVID-19 pandemic, which altered exposure and travel patterns, reducing opportunities for leishmaniasis transmission. Additionally, disruptions to health care services and public health reporting during the pandemic may have contributed to the underreporting of cases. As the pandemic&#x2019;s effects continue to influence public behavior, travel, and health care practices, it is probable that these factors are still impacting leishmaniasis incidence. The decrease in reported cases after 2018, along with the continued lower incidence observed in 2023, may reflect these ongoing effects and possible changes in environmental factors affecting the sandfly population.</p><p>This further emphasizes the necessity of nationwide reporting standards and greater education efforts among health care providers for ensuring early leishmaniasis detection and treatment. Diagnosis should include clinical assessment, travel history assessment, and laboratory tests such as skin biopsies and polymerase chain reaction assays. Early treatment is crucial for preventing complications, including topical antiparasitic medications for localized cases and systemic therapies for more severe involvement.</p></sec><sec id="s4-2"><title>Conclusion</title><p>This study&#x2019;s findings should encourage public health officials and clinicians to have a high level of suspicion for leishmaniasis and prioritize surveillance and reporting, particularly in endemic regions like Texas. Mitigating continued spread can be addressed by patient education on preventative measures, such as covering exposed skin, wearing Environmental Protection Agency&#x2013;registered insect repellent, and avoiding the outdoors after dusk. Medical personnel must be aware of important symptomatology to recognize leishmaniasis, including slowly ulcerating skin sores, swallowing difficulty, and nosebleeds. As numerous influences continue to increase leishmaniasis incidence, the United States must necessitate ongoing research and public health preparedness.</p></sec></sec></body><back><fn-group><fn fn-type="conflict"><p>None declared.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term id="abb1">DSHS</term><def><p>Department of State Health Services</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><label>1</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Vries</surname><given-names>HJC</given-names> </name><name name-style="western"><surname>Schallig</surname><given-names>HD</given-names> </name></person-group><article-title>Cutaneous leishmaniasis: a 2022 updated narrative review into diagnosis and management developments</article-title><source>Am J Clin Dermatol</source><year>2022</year><month>11</month><volume>23</volume><issue>6</issue><fpage>823</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1007/s40257-022-00726-8</pub-id><pub-id pub-id-type="medline">36103050</pub-id></nlm-citation></ref><ref id="ref2"><label>2</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McIlwee</surname><given-names>BE</given-names> </name><name name-style="western"><surname>Weis</surname><given-names>SE</given-names> </name><name name-style="western"><surname>Hosler</surname><given-names>GA</given-names> </name></person-group><article-title>Incidence of endemic human cutaneous leishmaniasis in the United States</article-title><source>JAMA Dermatol</source><year>2018</year><month>09</month><day>1</day><volume>154</volume><issue>9</issue><fpage>1032</fpage><lpage>1039</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2018.2133</pub-id><pub-id pub-id-type="medline">30046836</pub-id></nlm-citation></ref><ref id="ref3"><label>3</label><nlm-citation citation-type="web"><article-title>Status of endemicity of cutaneous leishmaniasis data by country</article-title><source>World Health Organization</source><year>2023</year><month>09</month><day>29</day><access-date>2024-03-23</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://apps.who.int/gho/data/node.main.NTDLEISHCEND?lang=en">https://apps.who.int/gho/data/node.main.NTDLEISHCEND?lang=en</ext-link></comment></nlm-citation></ref><ref id="ref4"><label>4</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#x00E1;lez</surname><given-names>C</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>O</given-names> </name><name name-style="western"><surname>Strutz</surname><given-names>SE</given-names> </name><name name-style="western"><surname>Gonz&#x00E1;lez-Salazar</surname><given-names>C</given-names> </name><name name-style="western"><surname>S&#x00E1;nchez-Cordero</surname><given-names>V</given-names> </name><name name-style="western"><surname>Sarkar</surname><given-names>S</given-names> </name></person-group><article-title>Climate change and risk of leishmaniasis in North America: predictions from ecological niche models of vector and reservoir species</article-title><source>PLoS Negl Trop Dis</source><year>2010</year><month>01</month><day>19</day><volume>4</volume><issue>1</issue><fpage>e585</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0000585</pub-id><pub-id pub-id-type="medline">20098495</pub-id></nlm-citation></ref><ref id="ref5"><label>5</label><nlm-citation citation-type="web"><article-title>Human cases of zoonotic diseases in Texas: 2020-2024</article-title><source>Texas Department of State Health Services</source><access-date>2025-06-13</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://www.dshs.texas.gov/notifiable-conditions/zoonosis-control/zoonotic-disease-cases/human-cases-2020-2024">https://www.dshs.texas.gov/notifiable-conditions/zoonosis-control/zoonotic-disease-cases/human-cases-2020-2024</ext-link></comment></nlm-citation></ref></ref-list></back></article>